response and outcomes with tkis in hcc
Published 6 years ago • 65 plays • Length 6:20Download video MP4
Download video MP3
Similar videos
-
5:34
hcc: role of radiotherapy and measuring response
-
7:35
checkpoint inhibitors versus tki therapy in hcc
-
8:23
comparative data in available tkis for hcc
-
5:40
multitargeted tki therapy in metastatic hcc
-
4:32
overview and diagnosis of hcc
-
2:06
dr. llovet on combination therapy in hcc
-
2:32
dr. el-khoueiry on choosing between immunotherapy agents and tkis in hcc
-
5:40
sorafenib initiation after tace in hcc
-
1:05:05
hcc: optimizing outcomes with new and emerging treatment approaches
-
7:29
understanding how best to sequence in advanced hcc
-
1:22
dr. el-khoueiry on choosing between lenvatinib and sorafenib in hcc
-
13:51
how to integrate new agents in hcc: the role of tkis
-
5:28
assessing response to sorafenib
-
6:51
hcc: use of lenvatinib and sorafenib
-
28:11
hepatocellular carcinoma - molecular approaches to treatment
-
2:18
dr. finn on biomarkers of response in hcc
-
1:10
the impact of immunotherapy and checkpoint inhibition in treating hcc
-
6:39
emerging second-line therapies in hcc
-
3:26
role of vegf tkis for treatment of hcc